AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Amphastar Pharmaceuticals, Inc.
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001SCM4W2
25.14▼ 0.90 (-3.46%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
26.04
Day's Range
24.62 – 25.91
52-Week Range
16.65 – 29.53
Volume
470.2K
Avg Volume
480.8K
Share Statistics
Shares Outstanding
Employees
1,976
Exchange
XNAS
Listed
2014-06-25
Share count as of July 31, 2026

Amphastar Pharmaceuticals, Inc. (AMPH) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Amphastar Pharmaceuticals, Inc. (AMPH)
What is Amphastar Pharmaceuticals, Inc.'s Market Cap?
Amphastar Pharmaceuticals, Inc.'s Market Cap is $1.1B, based on as-reported figures from SEC (XBRL) filings.
What is Amphastar Pharmaceuticals, Inc.'s Enterprise Value?
Amphastar Pharmaceuticals, Inc.'s Enterprise Value is $1.4B, based on as-reported figures from SEC (XBRL) filings.
What is Amphastar Pharmaceuticals, Inc.'s Trailing P/E?
Amphastar Pharmaceuticals, Inc.'s Trailing P/E is 13.6×, based on as-reported figures from SEC (XBRL) filings.
What is Amphastar Pharmaceuticals, Inc.'s Price / Sales?
Amphastar Pharmaceuticals, Inc.'s Price / Sales is 1.5×, based on as-reported figures from SEC (XBRL) filings.
What is Amphastar Pharmaceuticals, Inc.'s EV / Revenue?
Amphastar Pharmaceuticals, Inc.'s EV / Revenue is 1.9×, based on as-reported figures from SEC (XBRL) filings.
What is Amphastar Pharmaceuticals, Inc.'s EV / EBITDA?
Amphastar Pharmaceuticals, Inc.'s EV / EBITDA is 8.1×, based on as-reported figures from SEC (XBRL) filings.
What is Amphastar Pharmaceuticals, Inc.'s Revenue (TTM)?
Amphastar Pharmaceuticals, Inc.'s Revenue (TTM) is $730.0M, based on as-reported figures from SEC (XBRL) filings.
What is Amphastar Pharmaceuticals, Inc.'s Net Income (TTM)?
Amphastar Pharmaceuticals, Inc.'s Net Income (TTM) is $78.5M, based on as-reported figures from SEC (XBRL) filings.
What is Amphastar Pharmaceuticals, Inc.'s EBITDA?
Amphastar Pharmaceuticals, Inc.'s EBITDA is $171.4M, based on as-reported figures from SEC (XBRL) filings.
What is Amphastar Pharmaceuticals, Inc.'s Diluted EPS (TTM)?
Amphastar Pharmaceuticals, Inc.'s Diluted EPS (TTM) is 1.85, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · AMPHAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Net Revenues:
Revenues
YoY growth+5.4%+0.4%-1.8%+0.3%
Cost of revenues
Gross profit
% of revenue50.8%41.1%46.8%51.4%
Operating expenses:
Selling, distribution, and marketing
General and administrative
Research and development
Total operating expenses
% of revenue29.2%33.1%27.3%38.2%
Income from operations
% of revenue21.6%8.0%19.4%13.2%
Non-operating income (expenses):
Interest income
Interest expense
Other income (expenses), net
Total non-operating income (expenses), net
Income before income taxes
Income tax provision
Net income
% of revenue16.5%3.8%13.3%9.0%
Basic
Diluted